Skip to main content

Abiraterone Side Effects

Medically reviewed by Drugs.com. Last updated on Feb 19, 2023.

Applies to abiraterone: oral tablet.

Serious side effects of Abiraterone

Along with its needed effects, abiraterone may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking abiraterone:

More common

Less common

Rare

Incidence not known

Other side effects of Abiraterone

Some side effects of abiraterone may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to abiraterone: oral tablet.

Endocrine

Uncommon (0.1% to 1%): Adrenocortical insufficiency[Ref]

Hepatic

Very common (10% or more): Elevated ALT (up to 41.9%), elevated AST (up to 37.3%)

Common (1% to 10%): Elevated total bilirubin

Postmarketing reports: Fulminant hepatitis, acute liver failure and death[Ref]

Cardiovascular

Very common (10% or more): Hot flush (up to 22.3%), hypertension (up to 21.6%)

Common (1% to 10%): Arrhythmia, chest pain/chest discomfort, angina pectoris, atrial fibrillation, tachycardia, myocardial infarction/ischemia, cardiac failure (e.g., congestive heart failure, left ventricular dysfunction, decreased ejection fraction)

Frequency not reported: QT prolongation[Ref]

Musculoskeletal

Very common (10% or more): Joint swelling/discomfort (up to 30.3%), muscle discomfort (up to 26.2%), contusion (up to 13.3%)

Common (1% to 10%): Groin pain, fractures, falls

Postmarketing reports: Rhabdomyolysis, myopathy[Ref]

Hematologic

Very common (10% or more): Lymphopenia (up to 38.2%), anemia[Ref]

Metabolic

Very common (10% or more): Hypertriglyceridemia (up to 62.5%), hyperglycemia (up to 56.6%), hypernatremia (up to 32.8%), hypokalemia (up to 28.3%), fluid retention/edema (up to 26.7%), hypophosphatemia (up to 23.8%), elevated alkaline phosphatase, hypercholesterolemia[Ref]

Renal

Frequency not reported: Renal failure[Ref]

Other

Very common (10% or more): Fatigue (up to 39.1%)

Common (1% to 10%): Sepsis, pyrexia[Ref]

Respiratory

Very common (10% or more): Cough (up to 17.3%), upper respiratory tract infection (up to 12.7%), dyspnea (up to 11.8%), nasopharyngitis (up to 10.7%)

Postmarketing reports: Non-infectious pneumonitis, allergic alveolitis[Ref]

Genitourinary

Very common (10% or more): Urinary tract infection (up to 12%), hematuria (up to 10.3%)

Common (1% to 10%): Urinary frequency, nocturia[Ref]

Psychiatric

Very common (10% or more): Insomnia (up to 13.5%)[Ref]

Gastrointestinal

Very common (10% or more): Constipation (up to 23.1%), diarrhea (up to 21.6%), dyspepsia (up to 11.1%), vomiting[Ref]

Dermatologic

Common (1% to 10%): Rash[Ref]

Frequently asked questions

References

1. Product Information. Zytiga (abiraterone). Centocor Inc. 2011.

2. Product Information. Yonsa (abiraterone). Sun Pharmaceutical Industries. 2018.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.